Clinical TrialsThe advancement of RAD 204 into a first-in-human Phase I trial in non-small cell lung cancer is a significant development for Radiopharm Theranostics.
Market ExpansionThe launch of American Depository Shares, with plans for a secondary listing on Nasdaq, positions Radiopharm for broader market exposure.
Market StrategyRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited/no use in radiopharmaceuticals, designed to de-risk development and limit competition.